Matthias Clauss, PhD
Matthias Clauss is a Senior Research Professor of Medicine and Microbiology & Immunology at the Indiana University School of Medicine in Indianapolis. Dr. Clauss has been continuously funded by the NIH for over 13 years and has published over 90 papers. Dr. Clauss's laboratory is focused on elucidating the role of HIV and other viruses in disease. He has received multiple academic and small business grants including R01s and SBIRs. His current R01 grant is focused on the role of extracellular vesicles in HIV-related comorbidities.
Dr. Clauss received his Ph.D. in Biochemistry from the German Cancer Center and the Ruprecht-Karls-University in Heidelberg, Germany and completed his postdoctoral fellowship at Columbia University.
Bernhard Maier, PhD
.jpg)
Dr. Maier started his scientific explorations in the Max-Planck Institute for Immunobiology with a pioneering dissertation on the activation of helper (Th) and regulatory (Treg) T cells. During his postdoctoral fellowship he applied antisense-RNA technology to protect CD4+ T cells from infection by HIV at the National Institutes of Health (NIH). His group at the Max-Planck Institute generated HIV-specific cytotoxic T cells from uninfected donors that efficiently eliminated cells infected with HIV-1, HIV-2, and SIV by targeting conserved epitopes of Nef, a major pathogenic protein of HIV. With his colleagues at the University of Virginia, he found that a short isoform of the tumor suppressor P53 plays a significant role in organismal aging and cancer incidence. At Indiana University, he identified the posttranslational hypusination of eIF5A to be a druggable target for the prevention of diabetes development. His publications improved our understanding of the molecular mechanisms that cause integrated stress responses and ablation of insulin-producing beta-cells. Dr. Maier's work on bacterial sepsis and kidney disease provided crucial insight into sepsis's temporal dynamics and staging to improve therapeutic intervention and survival.